Biomaterials For Cancer Therapeutics

Cancer can affect people of all ages, and approximately one in three people are estimated to be diagnosed with cancer during their lifetime. Extensive research is being undertaken by many different institutions to explore potential new therapeutics, and biomaterials technology is now being developed to target, treat and prevent cancer.

This unique book discusses the role and potential of biomaterials in treating this prevalent disease. The first part of the book discusses the fundamentals of biomaterials for cancer therapeutics. Chapters in part two discuss synthetic vaccines, proteins and polymers for cancer therapeutics. Part three focusses on theranosis and drug delivery systems, whilst the final set of chapters look at biomaterial therapies and cancer cell interaction.

This extensive book provides a complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancer. Biomaterials for cancer therapeutics is an essential text for academics, scientists and researchers within the biomedical industry, and will also be of interest to clinicians with a research interest in cancer therapies and biomaterials. * A complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancer* Discusses the fundamentals of biomaterials for cancer therapeutics* Discusses synthetic vaccines, proteins and polymers for cancer therapeutics Review: On the whole, the book is a combination of the fundamentals of cancer biology, guiding principles on the design of biomaterials and the clinical potential of these biomaterials, which is of interest to a broad audience involving chemists, biologist and material scientists. --Biomat.net, June 2014 Intended for researchers, this collection introduces new methods for delivering drugs to cancer cells and tumors and innovative technologies for treating cancers with biomaterials.

Needham .describes his low temperature-sensitive liposome (Thermodox) drug delivery system, which failed to meet its primary endpoint in a phase III trial of liver cancer. --ProtoView.com, February 2014